BliNK Biomedical

BliNK Biomedical SAS focuses on the discovery and development of first-in-class or best-in-class antibody-based treatments for life-threatening diseases such as cancer, with an emphasis on immuno-oncology disease targets. The company’s lead program is a monoclonal antibody targeting immune checkpoints, triggering an immune switch that makes tumors susceptible to the human immune system. Other programs in the company’s pipeline target a range of attractive, novel immuno-oncology and immune checkpoint targets, some of which are addressed through our unique approach. The antibodies under development have the potential to become next-generation anti-cancer therapies.